Table 4.
Comparison of baseline clinical characteristics of the validation cohort based on Brugada syndrome diagnosis after Sodium Channel Blocker Provocation Test.
| Overall (n = 197) |
Negative SCBPT (n = 150) |
Positive SCBPT (n = 47) |
p Value | |
|---|---|---|---|---|
| Age, years | 44.9 ± 13.7 | 44.1 ± 13.6 | 47.9 ± 13.7 | 0.101 |
| Sex Male, % (n) | 74.6 (147) | 73.3 (110) | 78.7 (37) | 0.459 |
| LVEF, % | 58.5 ± 4.6 | 58.2 ± 5.2 | 59.6 ± 4.1 | 0.463 |
| Flecainide administered, mg | 122 ± 11 | 128 ± 15 | 102 ± 12 | <0.0001 |
| Indication for test | ||||
| Suspicious ECG, % (n) | 24.4 (48) | 20 (30) | 38.3 (18) | 0.01 |
| Symptoms, % (n) | 8.1 (16) | 6.7 (10) | 12.8 (6) | 0.182 |
| Family history of BrS, % (n) | 39.6 (78) | 36.7 (55) | 48.9 (23) | 0.133 |
| Family history of sudden cardiac death, % (n) | 27.9 (55) | 36.7 (55) | 0 (0) | <0.0001 |